Stock chart
Analyses on Almeda Ventures (3)
- March 22, 2026March 22, 2026
- Follow-up
After Augmedics and FlexDex: Which Part of Almada's Book Still Holds Up
After Augmedics and FlexDex, Almada’s book still holds up mainly through Sensi, and more cautiously through MetaFlow. The rest of this pocket depends largely on funding, licensing, or liquidation, making it much weaker than the Level 3 headline suggests.
- Follow-up
Almada and BioProtect: How Much of the Deal Could Really Reach Cash
BioProtect's $10 million to $12 million headline is not yet equivalent to usable cash for Almada; until the MOU turns binding, closes, passes through tax and SAFE mechanics, and then through a separate capital-reduction path, most of the value remains conditional.
Almada Ventures 2025: Book Value Rose, Now It Has to Turn Into Cash
Almada moved in 2025 from a partnership reporting mostly potential to one that already showed accounting profit and one real monetization step, but the thesis still depends on converting private book value into accessible cash, first and foremost through BioProtect.
